FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma
Authors:
- 5 July 2016
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 19 (2) , 265-268
Abstract
Background Up to date, there are no data about FGFR2 expression and its predictive role in papillary RCC (pRCC) patients. The aim of the present study was to test FGFR2 expression and mutations for association with survival outcome in patients with pRCC. Methods Specimens of removed primary tumors from 214 untreated metastatic pRCC patients were evaluated by immunohistochemistry with FGFR2 antibody. FGFR2 mutations were assessed by PCR and direct sequencing, with DNA obtained from 62 paraffin-embedded pRCC samples. FGFR2 expression was tested for associations with progression-free survival (PFS), overall survival (OS) and best objective response. Results Expression of FGFR2 was observed in 23 % (49/214) of primary pRCC, mostly in cytoplasm of tumor cells. Expression of FGFR2 was significant lower in normal tissue of kidney (1 %, P = 0.001). FGFR2 S252W mutation was found in one patient (1.6 %), and no N549K mutation was detected. FGFR2 expression was strongly associated with a number of metastatic sites, type 2 of pRCC, lower nucleolar grade (P < 0.001). FGFR2-positive patients had significantly shorter OS and PFS (P < 0.05). On multivariate analysis, FGFR2 expression, MSKCC risk group and type of pRCC were found to be independent predictors of survival. Conclusions In this study, we described immunohistochemical expression of FGFR2 in a large series of pRCC specimens. FGFR2 expression was found to be prognostic factor for survival in patients with metastatic pRCC. FGFR2 mutations are rare across papillary types of RCC.Keywords
Funding Information
- Terry Fox Foundation
This publication has 7 references indexed in Scilit:
- Papillary renal cell carcinoma: A review of the current therapeutic landscapeCritical Reviews in Oncology/Hematology, 2015
- Fibroblast Growth Factor Receptor 1 as a Target for the Therapy of Renal Cell CarcinomaOncology, 2015
- Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02TTargeted Oncology, 2014
- Importance of Fibroblast Growth Factor Receptor in Neovascularization and Tumor Escape from Antiangiogenic TherapyClinical Genitourinary Cancer, 2012
- Fibroblast growth factor pathway in renal cell carcinoma.Journal of Clinical Oncology, 2010
- Molecular Diagnosis and Therapy of Kidney CancerAnnual Review of Medicine, 2010
- Resistance to targeted therapy in renal-cell carcinomaThe Lancet Oncology, 2009